文献速递血栓与止血

持续性化疗诱导血小板减少症中直接糖蛋白特异性血小板自身抗体的检测

Direct glycoprotein-specific platelet autoantibodies detected in a majority of patients with persistent chemotherapy-induced thrombocytopenia.
PubMed 文献 · J Thromb Haemost · 2026-07-10

36例(65.4%)患者自身抗体阳性,其中对GPIa/IIa反应性达97.2%,抗体阳性CIT患者平均抗体特异性数为2.2,光密度值和阳性抗体数与96例PA阳性ITP队列无显著差异。结论提示持续性CIT中可能存在免疫介导成分。

要点

  • 持续性CIT患者中65.4%可检出直接糖蛋白特异性血小板自身抗体。
  • 抗体阳性CIT患者对GPIa/IIa反应性高达97.2%,平均抗体特异性数2.2。
  • CIT患者抗体光密度值和阳性抗体数与ITP队列无显著差异。

核心结论

  • 持续性CIT患者中高比例存在强效血小板自身抗体,与ITP所见相当,提示潜在免疫介导成分。

研究设计与样本

  • 检测GPIIb/IIIa、GPIb/IX和GPIa/IIa自身抗体,由 centralized reference laboratory 完成。
  • 结果与96例PA阳性ITP参考队列比较。

主要发现

  • PA阳性CIT患者平均自身抗体特异性数为2.2。
  • 对GPIa/IIa反应性见于97.2%的PA阳性CIT患者。
  • 光密度值和阳性抗体数与ITP队列无显著差异。

关键数值与推荐

  • 持续性CIT定义为周期间血小板恢复不充分。
  • GPIa/IIa反应性97.2%。
  • 平均自身抗体特异性数2.2。

临床怎么用

  • 对持续性CIT患者可考虑检测直接糖蛋白特异性血小板自身抗体以识别免疫介导成分。

局限性

  • 尚未明确血小板自身免疫在CIT中的临床相关性和治疗意义,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chemotherapy-induced thrombocytopenia (CIT) is common in patients with solid tumors and often necessitates chemotherapy dose reduction or delay, compromising cancer outcomes. Persistent CIT, defined by inadequate platelet recovery between cycles, is typically attributed to cumulative myelosuppression, although emerging data suggest that immune dysregulation may also contribute. Platelet autoantibody (PA) testing, well studied in immune thrombocytopenia (ITP), has not been systematically examined in persistent CIT. OBJECTIVES: To characterize the prevalence and patterns of direct glycoprotein (GP)-specific platelet autoantibodies in patients with persistent CIT and to compare these findings with an ITP cohort tested using the same assay. METHODS: We retrospectively identified adults with solid tumors and persistent CIT who underwent direct PA testing at our institution from 2018 to 2022. Testing for autoantibodies to GPIIb/IIIa, GPIb/IX, and GPIa/IIa was performed at a centralized reference laboratory. Results were compared with a reference cohort of 96 PA-positive ITP patients. RESULTS: Fifty-five patients met the inclusion criteria. PA positivity was observed in 36 (65.4%) patients. Among PA-positive CIT patients, the mean number of autoantibody specificities was 2.2, with reactivity to GPIa/IIa detected in 97.2% of patients. Optical density values and the number of positive antibodies did not differ significantly from those of the ITP cohort. CONCLUSION: A surprisingly high proportion of patients with persistent CIT demonstrated robust platelet autoantibodies comparable to those seen in ITP. These findings suggest a potential immune-mediated component in persistent CIT and warrant further investigation into the clinical relevance and therapeutic implications of platelet-directed autoimmunity in CIT.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Song AB, Curtis BR, Al-Samkari H, et al. Direct glycoprotein-specific platelet autoantibodies detected in a majority of patients with persistent chemotherapy-induced thrombocytopenia. J Thromb Haemost. 2026. PMID: 42431313. doi:10.1016/j.jtha.2026.06.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。